Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya, JHM Schellens… - Cancer discovery, 2018 - AACR
Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya, JHM Schellens… - Cancer …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Although BRAF inhibitor monotherapy yields
response rates > 50% in BRAFV600-mutant melanoma, only approximately 5% of …
response rates > 50% in BRAFV600-mutant melanoma, only approximately 5% of …
[PDF][PDF] Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAFV600E-Mutant Colorectal Cancer
PJO Yaeger14, Y Humblet16, A Filip De Vos17, C Jan… - core.ac.uk
Activating gene mutations in the mitogen-activated protein kinase (MAPK) pathway are
frequently observed in cancer and promote tumor cell migration, proliferation, and survival …
frequently observed in cancer and promote tumor cell migration, proliferation, and survival …
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya… - Cancer …, 2018 - escholarship.org
Although BRAF inhibitor monotherapy yields response rates> 50% in BRAFV600-mutant
melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond …
melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond …
Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer
RB Corcoran, T André, CE Atreya… - Cancer …, 2018 - research.birmingham.ac.uk
Although BRAF inhibitor monotherapy yields response rates> 50% in BRAFV600-mutant
melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond …
melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond …
[HTML][HTML] Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya… - Cancer …, 2018 - ncbi.nlm.nih.gov
Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only~ 5% with BRAF V600E colorectal cancer (CRC) respond. Preclinical …
melanoma, only~ 5% with BRAF V600E colorectal cancer (CRC) respond. Preclinical …
[PDF][PDF] Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAFV600E-Mutant Colorectal Cancer
PJO Yaeger14, Y Humblet16, A Filip De Vos17, C Jan… - researchgate.net
Activating gene mutations in the mitogen-activated protein kinase (MAPK) pathway are
frequently observed in cancer and promote tumor cell migration, proliferation, and survival …
frequently observed in cancer and promote tumor cell migration, proliferation, and survival …
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
RB Corcoran, T André, CE Atreya, JHM Schellens… - Cancer …, 2018 - europepmc.org
Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only~ 5% with BRAF V600E colorectal cancer (CRC) respond. Preclinical …
melanoma, only~ 5% with BRAF V600E colorectal cancer (CRC) respond. Preclinical …
Combined BRAF, EGFR, and MEK Inhibition in Patients with-Mutant Colorectal Cancer.
RB Corcoran, T André, CE Atreya… - Cancer …, 2018 - dial.uclouvain.be
Although BRAF inhibitor monotherapy yields response rates> 50% in-mutant melanoma,
only approximately 5% of patients with colorectal cancer respond. Preclinical studies …
only approximately 5% of patients with colorectal cancer respond. Preclinical studies …
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya… - Cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …